Desalex

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Desalex

What is Desalex?

Desalex is an antihistamine medication used to manage symptoms associated with allergic reactions. It contains the active substance desloratadine, which is a long-acting tricyclic antagonist of selective peripheral histamine H1-receptors.

Mechanism of Action

The medication works by blocking the action of histamine, a natural substance in the body that causes allergic symptoms. By preventing histamine from binding to its receptors, the medication helps to relieve the discomfort associated with various allergic triggers. Unlike some older antihistamines, the active ingredient in Desalex is a non-sedating antihistamine, meaning it is less likely to cross the blood-brain barrier and cause drowsiness.

Primary Uses

Desalex is typically utilized to address symptoms occurring in two main types of allergic conditions:

  • Allergic Rhinitis: This includes symptoms such as sneezing, runny or itchy nose, itchy palate, and itchy, red, or watery eyes. These symptoms may occur seasonally or throughout the year.
  • Urticaria: This condition is characterized by the appearance of hives or wheals on the skin. The medication helps to alleviate the itching and reduce the size and number of these skin eruptions.

Physical Characteristics

Desalex is commonly available in several forms to accommodate different patient needs, including film-coated tablets and oral solutions. The tablets are generally small, round, and coated for ease of swallowing, while the oral solution provides an alternative for those who prefer liquid medication.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Desalex?

Possible Side Effects and Safety Information

The official safety profile for Desalex (desloratadine) is established through regulatory classification of adverse reactions observed in clinical trials and post-marketing surveillance. The incidence of adverse effects in trials was reported to be only slightly higher than that observed with placebo.


Frequency-Classified Adverse Reactions

Adverse events are categorized by frequency as defined in official regulatory documents:

  • Common (occurring in 1% to 10% of adults and adolescents): The most frequent effects reported include headache, fatigue or tiredness, and dry mouth. Other common reactions include pharyngitis and muscle pain.
  • Very Rare (reported from post-marketing experience): These are uncommon but significant reactions across different physiological systems, including seizures, hallucinations, serious hypersensitivity reactions (such as anaphylaxis and angioedema), tachycardia (rapid heart rate), palpitations, and hepatitis or jaundice (liver effects).
  • Frequency Not Known: This category includes events like QT prolongation (a change in heart rhythm), arrhythmia, and increased appetite or weight gain.

Safety Considerations for Special Populations

Official labeling addresses specific population safety constraints due to altered drug exposure or underlying risk:

Population Regulatory Safety Note
Renal / Hepatic Impairment Increased drug exposure (C max and AUC) is observed, particularly in severe impairment.
Pediatric Patients Caution is advised in patients with a medical or familial history of seizures due to reports of new-onset seizure.

Safety-Related Restrictions

Desalex is contraindicated in individuals with a known hypersensitivity to the active ingredient, desloratadine, or to its related precursor drug, loratadine, or any of the product's excipients. Furthermore, official documents advise administering the medication with caution in patients who have a medical or familial history of seizures.

Overdose and Emergency Response

Overdose: When to Seek Help

Official regulatory documents define the overdose profile for Desalex (desloratadine) based on symptoms documented in clinical studies involving high-dose exposures. Management of a desloratadine overdose is primarily symptomatic and supportive.

Documented Overdose Symptoms

Symptoms reported in studies following exposure to high doses (up to 9 times the recommended daily dose) include:

  • Drowsiness: A state of feeling sleepy or lethargic.
  • Headache: Pain in the head.
  • Tachycardia: An unusually rapid heart rate.

Emergency Actions

Immediate medical attention is required in the event of an overdose. The official guidance specifies seeking help by contacting a Poison Control Center or obtaining medical help immediately.

Call emergency services immediately if the individual:

  • Has collapsed or is unresponsive (cannot be awakened).
  • Has difficulty or trouble breathing.
  • Experiences a seizure.

Management procedures, as stated by regulatory bodies, focus on removing the unabsorbed drug and providing supportive care. It is noted that desloratadine and its active metabolite are not eliminated from the body by hemodialysis.

If any of the severe signs listed above are present, do not wait; contact emergency services immediately.

Therapeutic Uses of Desalex

What Desalex Treats: Main Uses and Benefits

Desalex (desloratadine) is primarily used in situations involving certain distressing symptoms related to systemic imbalance caused by allergic reactions. The medication is applied across therapeutic domains where additional symptomatic support is needed, in accordance with established therapeutic applications for the active ingredient.


Symptomatic Relief for Allergic Conditions

Desalex is commonly used to help with conditions characterized by periods of heightened symptoms, specifically allergic rhinitis (both seasonal and perennial forms) and chronic idiopathic urticaria (hives). It helps address symptom clusters that may become intense or disruptive, such as repetitive sneezing, runny nose, nasal congestion, and the itching and watering of the eyes. This support may contribute to improved day-to-day comfort during symptomatic periods by easing the overall symptom load.

The active ingredient is applied in managing manifestations of allergic disease, including nasal symptoms, ocular symptoms, and cutaneous symptoms like itching and wheals. It is relevant when supportive symptom management is appropriate, such as during phases when symptoms become more noticeable.

“The medication is designed to help patients cope more steadily with the daily discomfort associated with persistent or recurrent allergic manifestations.”


Quick Fact: Relief for Multiple Symptom Domains

Domain Conditions Key Benefit
Respiratory/Ocular Seasonal and perennial allergic rhinitis May assist with maintaining functional stability (e.g., may help ease sneezing and tearing).
Dermatological Chronic idiopathic urticaria (Hives) Provides support that may help ease the overall symptom burden of discomfort related to itching and wheals.

Regulatory References

  1. NIH DailyMed official Desloratadine Labeling

Eligibility and Restrictions for Use

Who Can and Cannot Use Desalex (Desloratadine)?

Official regulatory documents define strict criteria for the use of Desalex, focusing on patient age, reproductive status, and pre-existing medical conditions.


Contraindicated Populations (Must Not Use)

Classification Population Status
Hypersensitivity Patients allergic to desloratadine, loratadine, or any of the product’s excipients. Contraindicated
Hereditary Disorders Patients with rare hereditary issues like galactose intolerance or total lactase deficiency (for certain formulations). Contraindicated

Conditional and Restricted Use

Eligibility is limited or requires caution in several populations:

  • Infants: Use is not established for children below 6 months of age. Use of the 5 mg tablet is restricted to ages 12 and above.
  • Organ Impairment: Adult patients with renal or hepatic impairment require caution, and regulatory labels recommend a specific modification to the regimen.
  • Pregnancy and Lactation: Use during pregnancy is preferable to avoid. During lactation, a decision must be made to discontinue the drug or discontinue nursing.
  • Seizure History: Patients with a medical or familial history of seizures require caution upon administration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Clinical trials have evaluated the co-administration of Desalex (desloratadine) with certain other medications, specifically focusing on the potential for pharmacokinetic and pharmacodynamic interactions.


Documented Pharmacokinetic Interactions

Desloratadine metabolism is susceptible to inhibition by certain drugs. Co-administration with the antibacterial Erythromycin or the antifungal Ketoconazole has been shown to increase the plasma concentrations (exposure) of desloratadine and its primary metabolite, 3-hydroxydesloratadine.

However, this increase in drug exposure was not associated with any clinically relevant changes in the safety profile of desloratadine, including no significant changes in electrocardiographic parameters such as the QTc interval.


Documented Pharmacodynamic Interactions

In clinical pharmacology trials, Desalex taken concomitantly with alcohol did not increase the impairment in performance or the increase in sleepiness caused by alcohol alone. Therefore, Desalex is generally considered not to potentiate the central nervous system (CNS) depressant effects of alcohol at the recommended dose.

Despite this clinical finding, cases of alcohol intolerance and intoxication have been reported during post-marketing use, and caution is advised regarding concomitant use.


Considerations for Special Populations

The systemic exposure to Desloratadine may be significantly higher in patients with severe renal impairment or hepatic impairment, as well as in individuals identified as slow metabolizers of desloratadine. Although not strictly an interaction with another substance, these conditions can necessitate careful consideration or dosage adjustment.

Mechanism of Action

Desalex (desloratadine) functions as a long-acting, selective peripheral Histamine H1 Receptor inverse agonist. Its primary biological target is the human H1-receptor, predominantly located on endothelial cells, smooth muscle, and mast cells throughout the periphery. The inverse agonism binding interaction shifts the H1-receptor into an inactive conformation, stabilizing the receptor’s basal state and blocking the conformational change that would normally be induced by endogenous histamine binding.

Intracellularly, this inhibition prevents the Gq protein coupling cascade that is typically activated by histamine-bound H1-receptors. The molecular consequence is the suppression of downstream signaling pathways, including the reduction of phosphatidylinositol hydrolysis and the subsequent release of calcium from intracellular stores. Additionally, desloratadine modulates inflammatory cell activity by inhibiting the release of pro-inflammatory mediators and chemokines from human mast cells and basophils in vitro. The system-level physiological consequence of this selective peripheral H1-receptor blockade is the attenuation of histamine-induced vasodilation, reduction of increased vascular permeability, and modulation of smooth muscle contraction in susceptible tissues. The compound is limited in its capacity to cross the blood-brain barrier, resulting in selective peripheral activity.

Dosage and Administration Information

Administration of Desalex: Official Guidelines

Desalex (desloratadine) is administered exclusively via the oral route, available as tablets, orally disintegrating tablets (ODT), and an oral solution. The dosage schedules establish a fixed regimen for use, with specific adjustments required for certain populations. The drug may be taken without regard to meals and should be administered once daily.


Standard Dosing and Frequency

Age Group Standard Daily Dose (Desloratadine) Administration Schedule
Adults and Adolescents (12 years and older) 5 mg (one tablet or 10 mL of solution) Once Daily
Children 6–11 years 2.5 mg (one ODT or 5 mL of solution) Once Daily
Children 6–11 months 1 mg (2 mL of solution) Once Daily

Special Administration Instructions

For adult patients with hepatic or renal impairment, it is specified that a reduction in exposure is necessary. A starting dose of 5 mg every other day is recommended based on pharmacokinetic data. Dosing recommendations for children with liver or kidney impairment are not established.

Specific preparation steps depend on the formulation: the oral solution must be measured using a calibrated dropper or syringe to ensure accuracy. Orally disintegrating tablets must be removed from their blister immediately prior to use and placed on the tongue to dissolve, which can be swallowed with or without water.

Regarding the course duration, treatment for intermittent conditions (symptoms for less than 4 days per week or less than 4 weeks) may be discontinued upon symptom resolution and reinitiated upon their reappearance. For persistent conditions, continued daily treatment may be proposed during periods of exposure. If a dose is missed, the patient should take it as soon as possible, but must not take a double dose to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Desalex


Evidence for Use in Allergic Rhinitis

Research exploring Desalex (desloratadine) for symptoms associated with both seasonal and perennial allergic rhinitis is founded primarily on short-term, controlled studies. These include multiple large randomized controlled trials (RCTs) compared to a placebo. Researchers concentrated on outcomes related to physical discomfort and systemic or functional imbalance. Studies monitored patient-reported outcomes describing perceived discomfort, such as sneezing, runny nose, and ocular symptoms. The trials reported patterns where the group assigned Desalex recorded lower composite symptom scores compared to the placebo groups over the study period. What remains uncertain is the limited body of research from direct comparisons against other second-generation antihistamines, and the short duration of core trials provides only limited insight into long-term outcomes.


Evidence for Use in Chronic Idiopathic Urticaria (Hives)

Research on Desalex for Chronic Idiopathic Urticaria (CIU), or chronic hives, explored a condition characterized by fluctuating manifestations. Evidence relies on placebo-controlled, double-blind RCTs and subsequent Systematic Reviews. The primary outcomes monitored were changes in the cutaneous symptoms, encompassing the severity of pruritus (itching) and the overall number and size of the wheals. Studies reported measured changes in these key outcomes over the four-to-six-week observation periods. Data monitored for patterns related to patient-reported scores tracking wheal size and the intensity of itching in the studied populations. Limited information is available concerning the evidence structure for sustained management of CIU over long periods.


Research in Special Populations and Age Groups

Desalex was studied for use across a range of age groups. The evidence base includes specific clinical trials where the compound was observed in pediatric populations, with studies conducted in children down to 6 months of age. Research also examined groups of adolescents and older adults in the broader trials. The results apply only to the populations studied, and data for certain complex groups often remain insufficient within the core controlled trial summaries.


What Remains Uncertain in the Evidence Base

The research highlights what is known and what is still uncertain. One key limitation is that comparative evidence is lacking in terms of direct, randomized head-to-head studies against other treatments currently available. Because follow-up durations were limited in the core trials, the long-term effects are not fully established, particularly concerning the management of persistent conditions over many years. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials
  2. Adult and paediatric poor metabolisers of desloratadine: an assessment of pharmacokinetics and safety

Frequently Asked Questions (FAQ)

Common questions about Desalex (FAQ)


Q: How quickly does Desalex start working after I take it?

A: Studies on how the drug moves through the body, known as pharmacokinetics, indicate that it is absorbed quickly. Official information notes that the concentration in the blood reaches its maximum in about 3 hours, and effects are typically observed in some individuals as early as one day after the start of therapy.

Q: How long do the effects of Desalex usually last?

A: Desalex is classified as a long-acting antihistamine. The drug has an elimination half-life of approximately 27 hours, according to official pharmacokinetic data. This long-lasting activity is consistent with the drug’s official once-daily administration schedule.

Q: Can Desalex be taken alongside other cold and flu medications?

A: Regulatory documents address the use of desloratadine in fixed combinations with a common decongestant ingredient, pseudoephedrine sulfate. This fixed combination is intended for use when both antihistamine and decongestant activity are indicated. Information regarding co-administering specific medications can be found in the official drug labeling.

Q: What is the main difference between Desalex and loratadine?

A: Official drug information describes Desalex (desloratadine) as the active metabolite of loratadine. In simple terms, this means that after a person takes loratadine, their body converts it into desloratadine, which is the substance primarily responsible for the antihistamine effect.

Q: Is Desalex indicated for long-term daily use?

A: Official guidelines allow for continued daily treatment for persistent conditions, such as chronic hives or rhinitis that lasts four weeks or more. However, research evidence summaries indicate that while the safety profile is established through controlled trials, long-term data extending over many years is limited in core regulatory documents.

Q: Can driving ability be affected after taking Desalex?

A: Official product information states that at the recommended dose, Desalex generally does not cause sleepiness or impairment that affects the ability to drive or operate machinery. However, regulatory documents note that responses may vary between individuals, and attention should be paid to the common side effect of fatigue.

Q: What should be done if too much Desalex is accidentally taken?

A: In the event of an overdose, official prescribing information states that immediate professional medical attention or contacting a poison control center is advised. The label notes that removal of unabsorbed drug should be considered as a clinical measure.

Q: What is Desalex used for besides the main allergy list?

A: The official indication list covers allergic rhinitis and chronic idiopathic urticaria (hives). Beyond these primary uses, drug information also notes that Desalex has been studied and used to improve nasal and nonnasal symptoms in patients with seasonal allergic rhinitis who also have concomitant mild to moderate asthma.

Q: Is Desalex the same type of drug as other common allergy pills?

A: Regulatory documents classify Desalex as a second-generation antihistamine. This class of drug is described as being selective and peripherally-acting, which is the scientific basis for its classification as non-sedating compared to older antihistamine types.

Q: Is Desalex available over the counter or is it only by prescription?

A: In the United States, Desalex (Clarinex) is currently available only with a prescription. However, the regulatory status can vary by country, and the chemical desloratadine is available without a prescription in some other jurisdictions.

Q: Is there a generic version of Desalex available?

A: Yes, the active ingredient, desloratadine, is available in generic formulations in addition to being sold under the brand name Desalex.

Q: Can Desalex cause weight gain?

A: Regulatory documents list both increased appetite and weight gain as adverse reactions reported during post-marketing surveillance. These effects fall under the frequency category of 'Frequency Not Known' in the official safety information.

Q: Is there information on Desalex use in elderly patients?

A: Clinical trials included patients aged 65 and over. Official information states that no general difference in safety or effectiveness was observed between older and younger adult patients. However, a note of caution is advised for any elderly patients who have pre-existing kidney or liver impairment.

Q: Is Desalex effective for pet allergies?

A: Official indications cover perennial allergic rhinitis, which includes year-round triggers such as those found indoors, like pet dander or house dust mites. Studies have focused on improving the symptoms associated with this type of long-term allergy.

Q: Can Desalex affect my mood or cause nervousness?

A: Official regulatory documents list changes in mental status. Hallucinations are noted as a 'Very Rare' adverse reaction, and reports of seizures and psychomotor hyperactivity (a state of restlessness and agitation) have also been recorded in post-marketing data.

Q: What do regulatory documents say about using Desalex during pregnancy or breastfeeding?

A: Official labeling advises that Desalex should be used during pregnancy only if the potential benefit is determined to justify the potential risk to the fetus, as comprehensive human data are limited. It is also known to pass into breast milk, and its use while breastfeeding is generally not recommended due to potential risk to the infant.

Q: Is Desalex classified as an anti-inflammatory medication?

A: While its primary function is blocking the H1-receptor, official descriptions note that Desalex also has effects that modulate inflammatory cell activity. Specifically, it inhibits the release of certain pro-inflammatory mediators and chemokines from mast cells and basophils observed in laboratory studies (in vitro).

Q: Can children use Desalex?

A: Yes, Desalex is officially indicated and studied for use in pediatric populations. Specific dosage recommendations are provided in regulatory documents for children as young as 6 months of age for the treatment of perennial allergic rhinitis and chronic idiopathic urticaria.

Q: Are there specific foods or drinks to avoid when using Desalex?

A: Clinical trials have shown that taking Desalex with food, including grapefruit juice, does not affect its absorption or effectiveness. Therefore, official instructions state that the drug may be taken without regard to meals.

Q: Why do official documents mention Desalex might cause tiredness?

A: Although Desalex is a selective peripheral antihistamine designed to have limited brain penetration, official regulatory sources list fatigue or tiredness as a common side effect. This is an observed effect documented in clinical trials, even in the absence of significant central nervous system sedation.

Q: What research supports the use of Desalex for chronic hives?

A: Research evidence includes placebo-controlled, double-blind Randomized Controlled Trials (RCTs). The studies focused on measured improvements in key outcomes, including the severity of pruritus (itching) and the overall number and size of the wheals in patients with Chronic Idiopathic Urticaria (hives).

Q: What are the less common side effects listed for Desalex in official documents?

A: The official safety profile includes categories for adverse effects that are less common. These include 'Very Rare' reactions (such as hallucinations, seizures, tachycardia, and hepatitis) and those of 'Frequency Not Known' (such as QT prolongation and weight gain).

Q: What is the general expectation for how long someone might need to take Desalex for seasonal allergies?

A: For intermittent conditions like seasonal allergies (where symptoms last less than four days per week or less than four weeks), official guidance states that treatment may be discontinued upon symptom resolution and reinitiated if symptoms return. For persistent conditions, continued daily treatment may be proposed.

Q: What does 'selective peripheral H1-receptor antagonist' mean in simple terms?

A: This term means the drug primarily works on H1 receptors located outside of the brain (peripheral), making it selective for allergy symptoms in the body. It acts as an antagonist (or inverse agonist), meaning it blocks the action of the chemical histamine that causes allergy symptoms.

How should Desalex be stored and disposed of?

Storage and Disposal of Desloratadine (Desalex)

Official regulatory guidelines strictly define the conditions required to store and handle desloratadine to maintain its stability.

Required Storage Conditions

Desloratadine tablets must be stored at controlled room temperature, maintaining an environment between 15 C and 30 C (59 F and 86 F), and must not be stored above 30 C or frozen. The product requires protection; therefore, it must be stored in the original package to shield it from moisture and light. Furthermore, the medicine must always be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Desloratadine must not be disposed of in household waste or wastewater. The product should be discarded only in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Desalex found in:

A-Z Index: